Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accelerate Diagnostics, IncAXDX · Entity 78156 | Director · 10% owner | December 03, 2024 | December 03, 2024 |
| Aspira Women's Health Inc.AWHL · Entity 7871 | 10% owner | June 05, 2026 | June 09, 2026 |
| BIODESIX INCBDSX · Entity 6053 | 10% owner · Emeritus Director | August 12, 2026 | August 13, 2026 |
| BIOLASE, INCBIOL · Entity 11470 | 10% owner | February 11, 2020 | May 15, 2020 |
| Neos Therapeutics, Inc.NEOS · Entity 141061 | 10% owner | February 17, 2017 | February 17, 2017 |
| QUIDEL CORP /DE/QDEL · Entity 126712 | Director · 10% owner | May 14, 2020 | May 18, 2020 |
| STERICYCLE INCSRCL · Entity 80873 | Director | April 30, 2018 | May 02, 2018 |
| YIELD10 BIOSCIENCE, INC.YTEN · Entity 88195 | 10% owner | December 20, 2023 | May 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accelerate Diagnostics, Inc
Report date December 03, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 8,310,388 |
Reported balance
After 2024-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-12-03 · Sale · Disposed 200,000 · Balance 8,310,388 F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes. F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust. |
| Common StockSEC Table I · non-derivative | Direct | 20,225 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,225 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,497 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,497 F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes.
F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.
F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Aspira Women's Health Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 4,046,051 |
Reported balance
After 2026-06-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-05 · Purchase · Acquired 222,222 · Balance 4,046,051 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2029-06-05 | IndirectBy Jack W. Schuler Living Trust | 300,000 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Purchase · Acquired 300,000 · Balance 300,000 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-09-17 | IndirectBy Jack W. Schuler Living Trust | 833,333 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 833,333 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2030-03-12 | IndirectBy Jack W. Schuler Living Trust | 1,801,265 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,801,265 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-07-26 | IndirectBy Jack W. Schuler Living Trust | 28,500 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 28,500 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-01-26 | IndirectBy Jack W. Schuler Living Trust | 8,888 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 8,888 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Common StockSEC Table I · non-derivative | Direct | 6,536 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,536 |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2027-07-09 | Direct | 6,536 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,536 |
Filing footnotes · ownership attribution and instrument terms
F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.
BIODESIX INC
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 555,810 |
Reported balance
After 2026-08-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-12 · Purchase · Acquired 15,000 · Balance 555,810 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler 2026 GRAT | 1,800,000 |
Reported balance
Holding disclosure · report date 2026-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,800,000 F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.
F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT.
BIOLASE, INC
Report date February 11, 2020 · Filed May 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 739,820 |
Reported balance
After 2020-02-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-02-11 · Sale · Disposed 1,307,931 · Balance 739,820 F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018. F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2020-02-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,000 F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018.
F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust.
Neos Therapeutics, Inc.
Report date February 17, 2017 · Filed February 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Jack W Schuler Living Trust | 2,338,671 |
Reported balance
Holding disclosure · report date 2017-02-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,338,671 F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
QUIDEL CORP /DE/
Report date May 14, 2020 · Filed May 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,103,249 |
Reported balance
After 2020-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-14 · Exercise / conversion · Acquired 2,100 · Balance 3,103,249 F1: Reflects release of restricted stock units that were previously reported on Form 4. F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-14 · Exercise / conversion · Disposed 2,100 · Balance 0 F3: Restricted stock units convert into common stock on a one-for-one basis. F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on Form 4.
F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any.
F3: Restricted stock units convert into common stock on a one-for-one basis.
F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date.
STERICYCLE INC
Report date April 30, 2018 · Filed May 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,078 |
Reported balance
After 2018-04-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-30 · Grant · Acquired 170 · Balance 2,078 F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.
YIELD10 BIOSCIENCE, INC.
Report date December 20, 2023 · Filed May 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 63,789 |
Reported balance
After 2023-12-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-12-20 · Sale · Disposed 36,000 · Balance 63,789 F1: This late filing is due to an inadvertent administrative error. F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split. F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This late filing is due to an inadvertent administrative error.
F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split.
F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date December 09, 2022 · Filed May 15, 2023
Section 16 reporting ended · disclosed 2023-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 36,595 |
Reported balance
After 2022-12-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-12-09 · Sale · Disposed 10,000 · Balance 36,595 F1: This late filing is due to an inadvertent administrative error. F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This late filing is due to an inadvertent administrative error.
F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 800 | $2.00 | $1,600.00 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 27 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 791,245 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| May 09, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 7,300 | $2.00 | $14,600.00 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 26 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 790,445 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| May 07, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 200 | $1.99 | $398.00 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 25 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 783,145 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| May 02, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 800 | $1.98 | $1,581.04 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 24 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 782,945 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| May 01, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 200 | $1.96 | $392.00 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 23 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 782,145 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 26, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 8,448 | $1.97 | $16,629.04 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 22 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 781,945 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 25, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 1,200 | $1.99 | $2,388.00 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 21 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 773,497 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 23, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 5,000 | $2.03 | $10,129.50 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 20 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 772,297 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 22, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 10,818 | $1.99 | $21,517.00 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 19 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 767,297 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 18, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 4,548 | $1.96 | $8,912.72 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 18 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 756,479 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 17, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 20,769 | $1.94 | $40,327.17 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 17 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 751,931 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 16, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 10,562 | $1.99 | $20,981.41 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 16 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 731,162 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 15, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 21,953 | $1.99 | $43,675.49 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 15 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 720,600 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 12, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 6,000 | $2.08 | $12,496.20 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 14 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 698,647 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 08, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 2,100 | $2.03 | $4,261.95 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 13 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 692,647 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 05, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 47,293 | $2.05 | $97,026.32 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 12 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 690,547 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 04, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 30,000 | $2.14 | $64,197.00 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 11 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 643,254 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 03, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 10,000 | $2.09 | $20,871.00 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 10 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 613,254 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 02, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 5,000 | $1.95 | $9,748.50 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 9 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 603,254 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| April 01, 2019 Filed Mar 27, 2020 21:07 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantStock Option (right to buy) · Derivative | 12,290 | $0.00 Strike: $21.02 | $0.00 |
DisclosureSEC source: 0001628280-20-004264 · wf-form4_158535765072903.xml · derivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,290 Underlying: Common Stock · 12,290 shares Expires 2029-04-01 F1 · date: This Form 4 was inadvertently not filed within the required time following the transaction date of April 1, 2019. F2 · derivative.exercise_date: The option vests in twelve equal monthly installments, with the first installment vesting on May 1, 2019. Read SEC document |
| April 01, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 146,230 | $1.96 | $286,259.85 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 8 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 598,254 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| March 29, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 11,243 | $2.09 | $23,492.25 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 7 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 452,024 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| March 28, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 8,970 | $2.11 | $18,935.67 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 6 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 440,781 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| March 27, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 100,000 | $2.05 | $204,580.00 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 5 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 431,811 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| March 26, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 42,745 | $2.23 | $95,415.39 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 4 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 331,811 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| March 25, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 30,014 | $2.31 | $69,347.35 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 3 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 289,066 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| March 22, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 147,645 | $2.37 | $350,154.88 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 259,052 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| March 21, 2019 Filed Jun 26, 2020 23:14 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 111,407 | $2.32 | $258,274.85 |
DisclosureSEC source: 0000899243-20-017804 · doc4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 111,407 F1 · ownership.nature: The shares are held by the Schuler Family Foundation, for which the Reporting Person serves as President. Read SEC document |
| March 14, 2019 Filed Jun 5, 2019 16:33 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | PurchaseCommon Stock | 552,427 | $1.21 | $668,491.91 |
DisclosureSEC source: 0001144204-19-029844 · tv523089_4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,822,908 F1 · shares: The reported securities were acquired by the Jack W. Schuler Living Trust. F3 · balance_after: The reported securities consist of the 2,838,148 shares of common stock owned by the Jack W. Schuler Living Trust, the 846 shares of common stock owned by the Renate Schuler Living Trust, and the 983,914 shares of common stock owned by the Schuler Family Foundation, in each case immediately following the 3/14/2019 acquisition of 552,427 shares of common stock by the Jack W. Schuler Living Trust . F4 · ownership.nature: Jack W. Schuler has an indirect pecuniary interest the reported securities through (i) the Jack W. Schuler Living Trust, as its trustee and beneficiary, (ii) the Renate Schuler Living Trust, as the spouse of its trustee and beneficiary, and (iii) the Schuler Family Foundation, as its president. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 10,000 | $18.48 | $184,800.00 |
DisclosureSEC source: 0001144204-19-004385 · tv512250_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,974,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.36 to $18.50, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| January 23, 2019 Filed Oct 5, 2021 16:01 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GiftCommon Stock | 689,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-019655 · wf-form4_163346401260762.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler GC 2010 Continuation Trust Disclosed balance after: 0 F3 · shares: These shares were gifted to other entities for which the reporting person does not have voting nor dispositive power over. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 20,000 | $14.57 | $291,400.00 |
DisclosureSEC source: 0001144204-19-001321 · tv510653_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,964,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.34 to $14.90, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 24, 2018 Filed Dec 27, 2018 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 20,000 | $10.53 | $210,600.00 |
DisclosureSEC source: 0001144204-18-066355 · tv509948_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,944,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.30 to $10.63, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 20,000 | $10.44 | $208,800.00 |
DisclosureSEC source: 0001144204-18-066221 · tv509910_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,924,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.30 to $10.50, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 02:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 151,550 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000899243-18-031746 · doc4.xml · derivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,276,110 Underlying: Common Stock · 151,550 shares Expires 2023-12-21 F3 · price: The reported securities are included within 3,031,002 units purchased by Partners for $1.60625 per unit. Each unit consists of one share of common stock and one warrant to acquire 5% of a share of Common Stock. F2 · derivative.exercise_date: The Living Trust owns warrants for 1,276,110 shares of Common Stock that are not currently exercisable due to restrictions on exercise that prevent the holder from exercising them to the extent it and its affiliates would beneficially own more than 19.99% of the Common Stock (the "19.99% Limitation"). F1 · ownership.nature: The shares and warrants are held of record by the Jack W. Schuler Living Trust (the "Living Trust"). Jack W. Schuler serves as the sole trustee of the Living Trust, and in such capacity may be deemed to beneficially own the shares and warrants held by the Living Trust. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 02:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock, par value $0.001 per share ("Common Stock") | 3,031,002 | $1.61 | $4,868,698.51 |
DisclosureSEC source: 0000899243-18-031746 · doc4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,550,678 F1 · ownership.nature: The shares and warrants are held of record by the Jack W. Schuler Living Trust (the "Living Trust"). Jack W. Schuler serves as the sole trustee of the Living Trust, and in such capacity may be deemed to beneficially own the shares and warrants held by the Living Trust. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 14:01 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 20,000 | $10.88 | $217,600.00 |
DisclosureSEC source: 0001144204-18-065957 · tv509707_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,904,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.69 to $10.93, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 20,000 | $11.21 | $224,200.00 |
DisclosureSEC source: 0001144204-18-065674 · tv509576_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,884,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.08 to $11.40, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 25,000 | $11.86 | $296,500.00 |
DisclosureSEC source: 0001144204-18-065359 · tv509506_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,864,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.53 to $12.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 25,000 | $12.37 | $309,250.00 |
DisclosureSEC source: 0001144204-18-065085 · tv509380_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,839,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.05 to $12.86, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 14, 2018 Filed Dec 17, 2018 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 15,000 | $12.86 | $192,900.00 |
DisclosureSEC source: 0001144204-18-064849 · tv509267_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,814,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.77 to $13.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 17:18 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 50,000 | $13.23 | $661,500.00 |
DisclosureSEC source: 0001144204-18-064702 · tv509216_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,799,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.08 to $13.50, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 34,000 | $13.83 | $470,220.00 |
DisclosureSEC source: 0001144204-18-064229 · tv509016_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,749,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.65 to $13.98, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| December 10, 2018 Filed Dec 11, 2018 14:03 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 10,000 | $13.89 | $138,900.00 |
DisclosureSEC source: 0001144204-18-064023 · tv508912_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,715,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.58 to $14.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the ""Issuer""), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the ?Foundation?). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation?s securities transactions, by virtue of the Foundation?s status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation?s transactions in the Issuer?s common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer?s common stock by the Foundation. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 14:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 10,000 | $13.97 | $139,700.00 |
DisclosureSEC source: 0001144204-18-063757 · tv508770_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,705,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at $13.97. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| November 28, 2018 Filed Nov 29, 2018 14:21 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 10,000 | $12.95 | $129,500.00 |
DisclosureSEC source: 0001144204-18-062273 · tv508112_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,695,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.94 to $12.95, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| November 27, 2018 Filed Nov 28, 2018 14:01 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 10,000 | $12.98 | $129,800.00 |
DisclosureSEC source: 0001144204-18-061926 · tv508040_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,685,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.91 to $12.99, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 14:36 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 25,000 | $12.95 | $323,750.00 |
DisclosureSEC source: 0001144204-18-061201 · tv507726_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,675,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.81 to $13.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 14:59 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 20,000 | $14.24 | $284,800.00 |
DisclosureSEC source: 0001144204-18-060234 · tv507375_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,650,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.20 to $14.26, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 14:38 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | OtherCommon Stock | 19,500 | $14.37 | $280,215.00 |
DisclosureSEC source: 0001144204-18-059275 · tv507084_4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,630,423 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.19 to $14.50, inclusive. The reporting person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The reporting person disclaims beneficial ownership of the shares of the Issuer owned by the Schuler Family Foundation (the "Foundation"). Although the reporting person is the President of the Foundation and makes investment decisions regarding the Foundation's securities transactions, by virtue of the Foundation's status as a 501(c)(3) tax-exempt organization, the reporting person may not, and in fact, does not personally derive any profit from the Foundation's transactions in the Issuer's common stock. As a result, this Form 4 is a voluntary report with respect to these purchases of the Issuer's common stock by the Foundation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.